We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Genmab is an international biotechnology company specializing in the creation and development of differentiated human antibody therapeutics for the treatment of cancer. Genmab is an international biotechnology company specializing in the creation and development of differentiated human antibody therapeutics for the treatment of cancer.
Company Announcement Interim analysis of PROLONG study met primary endpoint Further analysis of safety and efficacy data underway Interim analysis to be shared with regulatory...
COPENHAGEN K, Denmark, July 23, 2014 (GLOBE NEWSWIRE) -- Company Announcement Worldwide net sales of Arzerra(r) (ofatumumab) in Q2 2014 totaled GBP 12.8 million Genmab expects royalty...
New Phase III study of daratumumab in front line multiple myeloma Expected to start in Q4 2014 COPENHAGEN, Denmark, July 18, 2014 (GLOBE NEWSWIRE) -- Genmab A/S (Copenhagen:GEN...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | -14.62 | -5.33693509528 | 273.94 | 277.66 | 257.15 | 697 | 262.11011481 | CS |
4 | -6.99 | -2.62476061733 | 266.31 | 282.06 | 257.15 | 635 | 270.68209503 | CS |
12 | 6.31 | 2.49397257025 | 253.01 | 292.8 | 241.09 | 2229 | 270.8792787 | CS |
26 | -39.98 | -13.3578349482 | 299.3 | 310.56 | 241.09 | 1327 | 273.71769994 | CS |
52 | -119.155 | -31.482924896 | 378.475 | 381.925 | 241.09 | 1169 | 284.95742972 | CS |
156 | -164.68 | -38.8396226415 | 424 | 479.99 | 241.09 | 991 | 331.56786456 | CS |
260 | 58.32 | 29.0149253731 | 201 | 500.92 | 159.45 | 1197 | 320.15093899 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions